ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study by the German-Austrian acute myeloid leukemia study group

Haematologica

Volumn 100, Issue 3, 2015, Pages 324-330

  Paschka, Peter ^a   Schlenk, Richard F ^a   Gaidzik, Verena I ^a   Herzig, Julia K ^a   Aulitzky, Teresa ^a   Bullinger, Lars ^a   Späth, Daniela ^a   Teleanu, Veronika ^a   Kündgen, Andrea ^b   Köhne, Claus Henning ^c   Brossart, Peter ^d   Held, Gerhard ^e   Horst, Heinz A ^f   Ringhoffer, Mark ^g   Götze, Katharina ^h   Nachbaur, David ⁱ   Kindler, Thomas ^j   Heuser, Michael ^k   Thol, Felicitas ^k   Ganser, Arnold ^k   Döhner, Hartmut ^a   Döhner, Konstanze ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 2; LACTATE DEHYDROGENASE; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR RUNX1; ANTINEOPLASTIC AGENT; ASXL1 PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; FLT3 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; RUNX1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASXL1 GENE; CHROMOSOME ANALYSIS; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DEATH; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; ADOLESCENT; AGED; BONE MARROW; CLINICAL TRIAL; GENETICS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; SURVIVAL ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; ISOCITRATE DEHYDROGENASE; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; REPRESSOR PROTEINS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84924662543     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114157     Document Type: Article

References (35)

1. Fisher CL, Berger J, Randazzo F, Brock HW.A human homolog of Additional sexcombs, ADDITIONAL SEX COMBS-LIKE1, maps to chromosome 20q11. Gene.2003;306:115-126.
2. Abdel-Wahab O, Dey A. The ASXL-BAP1axis: new factors in myelopoiesis, cancer andepigenetics. Leukemia. 2013;27(1):10-15.
3. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated withpoor prognosis across the spectrum ofmalignant myeloid diseases. J HematolOncol. 2012;5:12.
4. Wang J, Li Z, He Y, et al. Loss of Asxl1 leadsto myelodysplastic syndrome-like diseasein mice. Blood. 2014;123(4):541-553.
5. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformationthrough loss of PRC2-mediatedgene repression. Cancer Cell. 2012;22(2):180-193.
6. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features ofde novo acute myeloid leukemia with additionalsex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086-4094.
7. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroupof older patients with primary cytogeneticallynormal AML within the ELNfavorable genetic category. Blood. 2011;118(26):6920-6929.
8. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acutemyeloid leukemia: prevalence and prognosticvalue. Haematologica. 2012;97(3):388-392.
9. Schnittger S, Eder C, Jeromin S, et al. ASXL1exon 12 mutations are frequent in AMLwith intermediate risk karyotype and areindependently associated with an adverseoutcome. Leukemia. 2013;27(1):82-91.
10. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated geneticprofiling in acute myeloid leukemia. N EnglJ Med. 2012;366(12):1079-1089.
11. El-Sharkawi D, Ali A, Evans CM, et al. ASXL1 mutations are infrequent in youngpatients with primary acute myeloidleukemia and their detection has a limitedrole in therapeutic risk stratification. LeukLymphoma. 2014;55(6):1326-1331.
12. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneichematopoietic stem-cell transplantationfrom matched related and matched unrelateddonors in younger adults with high-riskacute myeloid leukemia: German-Austriantrial AMLHD98A. J Clin Oncol. 2010;28(30):4642-4648.
13. Schlenk RF, Döhner K, Krauter J, et al. Alltransretinoic acid improves outcome inyounger adult patients with nucleophosmin-1 mutated acute myeloid leukemia – resultsof the AMLSG 07-04 randomized treatmenttrial. Blood. 2011;118(21):38-39 (abstract #80)
14. Schlenk RF, Germing U, Hartmann F, et al. High-dose cytarabine and mitoxantrone inconsolidation therapy for acute promyelocyticleukemia. Leukemia. 2005;19(6):978-983.
15. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloidleukemia: results from a comprehensivegenetic and clinical analysis from the AMLstudy group. J Clin Oncol. 2011;29(10):1364-1372.
16. Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations inyounger adult patients with acute myeloidleukemia: results of the AML Study Group(AMLSG). Blood. 2013;121(23):4769-4777.
17. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogeneticallynormal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
18. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequentgenetic alterations in acute myeloidleukemia and confer adverse prognosis incytogenetically normal acute myeloidleukemia with NPM1 mutation withoutFLT3 internal tandem duplication. J ClinOncol. 2010;28(22):3636-3643.
19. Schlenk RF, Taskesen E, van Norden Y, et al. The value of allogeneic and autologoushematopoietic stem cell transplantation inprognostically favorable acute myeloidleukemia with double mutant CEBPA. Blood. 2013;122(9):1576-1582.
20. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated geneASXL1 in myelodysplastic syndromes andchronic myelomonocytic leukaemia. Br JHaematol. 2009;145(6):788-800.
21. Korn EL. Censoring distributions as a measureof follow-up in survival analysis. StatMed. 1986;5(3):255-260.
22. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acutemyeloid leukemia in adults: recommendationsfrom an international expert panel, onbehalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
23. Kaplan E, Meier P. Nonparametric estimationfrom incomplete observations. J AmStat Assoc. 1958;53:457-481.
24. Therneau TM, Grambusch PM. Modelingsurvival data: extending the Cox model. New York, NY: Springer Verlag, 2000.
25. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missingdata in clinical trials. N Engl J Med.2012;367(14):1355-1360.
26. Harrell FE. Regression modeling strategies:with applications to linear models, logisticregression, and survival analysis. NewYork: Springer Verlag, 2001.
27. Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associatedgene ASXL1 in the myelodysplasticsyndromes and in acute myeloid leukemia. Leukemia. 2010;24(5):1062-1065.
28. Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion of ASXL1 and NPM1mutations in a series of acute myeloidleukemias. Leukemia. 2010;24(2):469-473.
29. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations inmyelodysplastic syndromes. N Engl J Med.2011;364(26):2496-2506.
30. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications ofdriver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627.
31. Devillier R, Gelsi-Boyer V, Brecqueville M, et al. Acute myeloid leukemia withmyelodysplasia-related changes are characterizedby a specific molecular pattern withhigh frequency of ASXL1 mutations. Am JHematol. 2012;87(7):659-662.
32. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associatedwith poor outcome in younger and olderpatients with cytogenetically normal acutemyeloid leukemia and with distinct geneand microRNA expression signatures. J ClinOncol. 2012;30(25):3109-3118.
33. Thol F, Friesen I, Damm F, et al. Prognosticsignificance of ASXL1 mutations in patientswith myelodysplastic syndromes. J ClinOncol. 2011;29(18):2499-2506.
34. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poorprognosis and acute transformation inchronic myelomonocytic leukaemia. Br JHaematol. 2010;151(4):365-375.
35. Kruidenier L, Chung CW, Cheng Z, et al. Aselective jumonji H3K27 demethylaseinhibitor modulates the proinflammatorymacrophage response. Nature. 2012;488(7411):404-408.P.